TY - JOUR T1 - Controlling the first wave of the COVID–19 pandemic in Malawi: results from a panel study JF - medRxiv DO - 10.1101/2021.02.21.21251597 SP - 2021.02.21.21251597 AU - Jethro Banda AU - Albert N. Dube AU - Sarah Brumfield AU - Amelia C. Crampin AU - Georges Reniers AU - Abena S. Amoah AU - Stéphane Helleringer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/23/2021.02.21.21251597.abstract N2 - Many African countries have experienced a first wave of the COVID–19 pandemic between June and August of 2020. According to case counts reported daily by epidemiological surveillance systems, infection rates remained low in most countries. This defied early models of the potential impact of COVID–19 on the continent, that projected large outbreaks and massive strain on health systems. Theories proposed to explain the apparently limited spread of the novel coronavirus in most African countries have emphasized 1) early actions by health authorities (e.g., border closures) and 2) biological or environmental determinants of the transmissibility of SARS-CoV-2 (e.g., warm weather, cross-immunity). In this paper, we explored additional factors that might contribute to the low recorded burden of COVID–19 in Malawi, a low-income country in Southeastern Africa. To do so, we used 4 rounds of panel data collected among a sample of adults during the first 6 months of the pandemic in the country. Our analyses of survey data on SARS-CoV-2 testing and COVID-related symptoms indicate that the size of the outbreak that occurred in June-August 2020 might be larger than recorded by surveillance systems that rely on RT-PCR testing. Our data also document the widespread adoption of physical distancing and mask use in response to the outbreak, whereas most measured patterns of social contacts remained stable during the course of the panel study. These findings will help better project, and respond to, future waves of the pandemic in Malawi and similar settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was partially supported by grant R01HD088516 (PI: Helleringer) from the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data collection procedures were approved by the institutional review boards of the National Health Sciences Research Committee in Malawi, the Johns Hopkins University School of Public Health and the London School of Hygiene and Tropical Medicine.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAt the moment, data are available upon reasonable request. The authors are preparing a data repository that will be made publicly available upon publication of study results. ER -